Vanda Pharmaceuticals Intends To Petition The US Supreme Court In Its HETLIOZ ANDA Litigation
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharmaceuticals plans to petition the US Supreme Court over its HETLIOZ ANDA litigation. The company argues that the US Court of Appeals for the Federal Circuit applied a flawed standard in assessing obviousness when it affirmed a lower court decision finding several of Vanda's HETLIOZ patents invalid.
October 20, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vanda Pharmaceuticals is planning to petition the US Supreme Court over its HETLIOZ ANDA litigation. This could potentially impact the company's patent rights and future revenues.
The news is directly related to Vanda Pharmaceuticals and its patent rights. If the Supreme Court rules against Vanda, it could potentially lose its exclusive rights to HETLIOZ, which could negatively impact its future revenues and profitability. Therefore, the short-term impact on the stock price is likely to be negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100